215654-61-8

Basic information

• Product Name: [2-[(4-Morpholinylcarbonyl)aMino]ethyl]-carbaMic acid, 1,1-diMethylethyl ester
• Synonyms: [2-[(4-Morpholinylcarbonyl)aMino]ethyl]-carbaMic acid, 1,1-diMethylethyl ester;RBYFBVIKKGFPPF-UHFFFAOYSA-N
• CAS NO: 215654-61-8
• Molecular Formula: C₁₂H₂₃N₃O₄
• Molecular Weight: 273.32872
• Product Categories: Heterocycles, Intermediates, Miscellaneous Reagents
• Mol File: 215654-61-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 496.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.138±0.06 g/cm3(Predicted)
• PKA: 12.80±0.46(Predicted)
• CAS DataBase Reference: [2-[(4-Morpholinylcarbonyl)aMino]ethyl]-carbaMic acid, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [2-[(4-Morpholinylcarbonyl)aMino]ethyl]-carbaMic acid, 1,1-diMethylethyl ester(215654-61-8)
• EPA Substance Registry System: [2-[(4-Morpholinylcarbonyl)aMino]ethyl]-carbaMic acid, 1,1-diMethylethyl ester(215654-61-8)

Safety Data

• Hazardous Substances Data: 215654-61-8(Hazardous Substances Data)

Usage

Uses

[2-[(4-Morpholinylcarbonyl)amino]ethyl]-carbamic acid, 1,1-dimethylethyl ester is a reagent used to synthesize β1-Arenoreceptor ligands.

Upstream product

• 15159-40-7 4-morpholinocarbonyl chloride 
• 57260-73-8 N-BOC-1,2-diaminoethane 

Downstream Products

• 1323276-50-1 (S)-N-(2-(3-(2-cyano-3-fluorophenoxy)-2-hydroxypropylamino)ethyl)morpholine-4-carboxamide 
• 69630-16-6 N-(2-aminoethyl)-4-morpholine carboxamide 
• 73210-73-8 (R)-xamoterol hemifumarate 
• 69630-21-3 (R)-N-(2-(3-(4-(benzyloxy)phenoxy)-2-hydroxypropylamino)ethyl)morpholine-4-carboxamide 
• 73210-73-8 (S)-xamoterol hemifumarate 

Relevant articles and documents

Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders

The beta-1 adrenergic receptor (ADRB1) is a promising therapeutic target intrinsically involved in the cognitive deficits and pathological features associated with Alzheimer’s disease (AD). Evidence indicates that ADRB1 plays an important role in regulating neuroinflammatory processes, and activation of ADRB1 may produce neuroprotective effects in neuroinflammatory diseases. Novel small molecule modulators of ADRB1, engineered to be highly brain permeable and functionally selective for the G protein with partial agonistic activity, could have tremendous value both as pharmacological tools and potential lead molecules for further preclinical development. The present study describes our ongoing efforts toward the discovery of functionally selective partial agonists of ADRB1 that have potential therapeutic value for AD and neuroinflammatory disorders, which has led to the identification of the molecule STD-101-D1. As a functionally selective agonist of ADRB1, STD-101-D1 produces partial agonistic activity on G protein signaling with an EC50 value in the low nanomolar range, but engages very little beta-arrestin recruitment compared to the unbiased agonist isoproterenol. STD-101-D1 also inhibits the tumor necrosis factor α (TNFα) response induced by lipopolysaccharide (LPS) both in vitro and in vivo, and shows high brain penetration. Other than the therapeutic role, this newly identified, functionally selective, partial agonist of ADRB1 is an invaluable research tool to study mechanisms of G protein-coupled receptor signal transduction.

Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.